The current emergency of the novel coronavirus SARS-CoV2 urged the need for broad-spectrum antiviral drugs as the first line of treatment. Coronaviruses are a large family of viruses that already challenged humanity in at least two other previous outbreaks and are likely to be a constant threat for the future. In this work we developed a pipeline based on in silico docking of known drugs on SARS-CoV1/2 RNA-dependent RNA polymerase combined with in vitro antiviral assays on both SARS-CoV2 and the common cold human coronavirus HCoV-OC43. Results showed that certain drugs displayed activity for both viruses at a similar inhibitory concentration, while others were specific. In particular, the antipsychotic drug lurasidone and the antiviral drug elbasvir showed promising activity in the low micromolar range against both viruses with good selectivity index.

Combined in silico and in vitro approaches identified the antipsychotic drug lurasidone and the antiviral drug elbasvir as SARS-CoV2 and HCoV-OC43 inhibitors

Donalisio M.
Co-first
;
Arduino I.;Lembo D.;
2021-01-01

Abstract

The current emergency of the novel coronavirus SARS-CoV2 urged the need for broad-spectrum antiviral drugs as the first line of treatment. Coronaviruses are a large family of viruses that already challenged humanity in at least two other previous outbreaks and are likely to be a constant threat for the future. In this work we developed a pipeline based on in silico docking of known drugs on SARS-CoV1/2 RNA-dependent RNA polymerase combined with in vitro antiviral assays on both SARS-CoV2 and the common cold human coronavirus HCoV-OC43. Results showed that certain drugs displayed activity for both viruses at a similar inhibitory concentration, while others were specific. In particular, the antipsychotic drug lurasidone and the antiviral drug elbasvir showed promising activity in the low micromolar range against both viruses with good selectivity index.
2021
189
105055
105064
Antiviral screening; Drug repurposing; HCoV-OC43; In silico docking; SARS-CoV2; Animals; Antiviral Agents; Benzofurans; COVID-19; Cell Line, Tumor; Chlorocebus aethiops; Computer Simulation; Coronavirus OC43, Human; Fibroblasts; Humans; Imidazoles; Lurasidone Hydrochloride; SARS-CoV-2; Vero Cells; Virus Replication; Drug Repositioning
Milani M.; Donalisio M.; Bonotto R.M.; Schneider E.; Arduino I.; Boni F.; Lembo D.; Marcello A.; Mastrangelo E.
File in questo prodotto:
File Dimensione Formato  
Antiviral research 2021.pdf

Accesso aperto

Tipo di file: PDF EDITORIALE
Dimensione 3.45 MB
Formato Adobe PDF
3.45 MB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2318/1815508
Citazioni
  • ???jsp.display-item.citation.pmc??? 15
  • Scopus 26
  • ???jsp.display-item.citation.isi??? 23
social impact